Novo Nordisk's new semaglutide trounces Lilly's scrappy Trulicity in diabetes trial

17th August 2017 Uncategorised 0

Novo Nordisk, fighting competition to its blockbuster Victoza, just posted data on a follow-up drug that gives it an edge over archrival Trulicity. That Lilly med has stolen share from Victoza, but the new head-to-head results, coupled with CV benefits in a previous trial, set up semaglutide to take it back.

More: Novo Nordisk's new semaglutide trounces Lilly's scrappy Trulicity in diabetes trial
Source: fierce